- CSR Summary Not Yet Available
- NCT00253175
- Primary Citation
- Data Specification Not Available
Trial Information
Generic NameTopiramateProduct NameTOPAMAX®Therapeutic AreaNervous System DiseasesEnrollment211% Female85.8%% White88.6%
Product ClassAnticonvulsantsSponsor Protocol NumberCAPSS-155Data PartnerJohnson & JohnsonCondition StudiedMigraine DisordersMean/Median Age (Years)40.5
Supporting Documentation
- Collected Datasets Available
- Protocol with Amendments Available
- Statistical Analysis Plan Available
- Clinical Study Report Available